Current Report Filing (8-k)
May 01 2020 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
April 27, 2020
electroCore,
Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38538
|
|
20-3454976
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification Number)
|
150 Allen Road, Suite 201
Basking Ridge, NJ 07920
(Address of principal executive offices and zip code)
(973) 290-0097
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
|
|
☐
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
☐
|
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
symbol(s)
|
|
Name of each exchange
on which registered
|
|
|
|
|
|
Common Stock, Par Value $0.001 Per Share
|
|
ECOR
|
|
NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On April 27, 2020, electroCore, Inc. (the Company) issued a press release with an update on the Companys ongoing non-invasive vagus nerve stimulation initiatives related to COVID-19, including the commencement of enrollment of COVID-19 patients in
an investigator-initiated, randomized, controlled clinical trial of nVNS therapy in Spain.
The Company also announced that a paper, entitled Use
of Non-Invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated with COVID-19: A Theoretical Hypothesis and Early Clinical Experience has gone
through peer review and been accepted for publication by the journal Neuromodulation: Technology at the Neural Interface. The paper is available at https://onlinelibrary.wiley.com/doi/abs/10.1111/ner.13172.
A copy of the press release is filed with this Form 8-K as Exhibit 99.1.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
electroCore, Inc.
|
May 1, 2020
|
|
/s/ Brian Posner
|
|
|
|
|
|
Brian Posner
|
|
|
Chief Financial Officer
|
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Apr 2023 to Apr 2024